Abvc Biopharma Inc 's ROA from the first quarter of 2026 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Abvc Biopharma Inc 's ROA in the first quarter of 2026?
Abvc Biopharma Inc recorded a cumulative net loss of $-7 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -33.35%.

However, within the Healthcare sector 464 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 3744, from total ROA ranking in the third quarter of 2025 at 4184.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	63.56 %	160.36 %	343.82 %	190.36 %	-33.91 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-7	-5	-5	-5	-8
Return On Assets (TTM)	-33.35 %	-28.58 %	-29.31 %	-47.69 %	-95.66 %
ABVC's Total Ranking	# 3744	# 4184	# 3862	# 3944	# 4210
Total Assets (TTM) in million	20	21	25	18	12
Seq. Total Assets Change	-6.31 %	-16.94 %	37.76 %	52.58 %	49.14 %
Seq. Net Income Change	-	-	-	-	-

ABVC's 5 Years Annual ROA >> Back to ABVC Management Effectiveness >> Compare ABVC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 184
Sector	# 465
Overall	# 3711

Return On Assets Statistics
High	Average	Low
-18.37 %	-96.53 %	-207.77 %
(Sep 30 2018)		(Dec 31 2018)

Financial Statements
Abvc Biopharma Inc 's Assets	$ 20 million	ABVC's Balance sheet
Abvc Biopharma Inc 's Income	$ -2 million	Quarterly ABVC's Income Statement
ABVC's Income by Division		See ABVC's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2018) FY 2018	(Dec 31 2017) FY 2017
Y / Y Total Assets Change	140.06 %	-30.24 %	14128.34 %	-96.36 %	1390.15 %
Total Assets in million	23	10	14	0	3
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-8	-16	-12	-4	-4
Annual Return On Assets	-36.52 %	-170.7 %	-87.87 %	-4260.08 %	-154.05 %

ABVC's 5 Years Annual ROA >> Back to ABVC Management Effectiveness >> Compare ABVC ROA to its Competitors

More Return On Assets Ratios
ABVC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ABVC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ABVC's Competitors
Subscribers only: Roa for Abvc Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for ABVC's Customers

You may also want to know
ABVC's Roi	ABVC's Inventory Turnover Ratio	ABVC's Growth Rates	ABVC's Dividend Comparisons
	ABVC's Profitability Ratios	ABVC's Asset Turnover Ratio	ABVC's Dividend Growth
ABVC's Roe	ABVC's Valuation Ratios	ABVC's Financial Strength Ratios	ABVC's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:12:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.